大葉大學圖書館 |

Developments in T cell based cancer immunotherapies[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.99406
書名/作者:	Developments in T cell based cancer immunotherapies/ edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang.
其他作者:	Ascierto, Paolo A.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	xv, 305 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Cancer - Immunotherapy.
標題:	Medicine.
標題:	Cancer - Research.
標題:	Immunology.
標題:	Molecular biology.
標題:	Cytology.
標題:	Biomedicine.
標題:	Cancer Research.
標題:	Molecular Medicine.
標題:	Cell Biology.
ISBN:	9783319211671
ISBN:	9783319211664
內容註:	1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.
摘要、提要註:	This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.
電子資源:	http://dx.doi.org/10.1007/978-3-319-21167-1

Developments in T cell based cancer immunotherapies[electronic resource] /
Developments in T cell based cancer immunotherapies[electronic resource] /edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang. - Cham :Springer International Publishing :2015. - xv, 305 p. :ill., digital ;24 cm. - Cancer drug discovery and development,2196-9906. - Cancer drug discovery and development..

1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.

ISBN: 9783319211671

Standard No.: 10.1007/978-3-319-21167-1doiSubjects--Topical Terms:

406740
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Developments in T cell based cancer immunotherapies[electronic resource] /
LDR:03062nam a2200325 a 4500 001 444392
003 DE-He213
005 20160408171134.0
006 m d
007 cr nn 008maaau
008 160715s2015 gw s 0 eng d
020 $a 9783319211671 $q (electronic bk.)
020 $a 9783319211664 $q (paper)
024 7 $a 10.1007/978-3-319-21167-1 $2 doi
035 $a 978-3-319-21167-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b D489 2015
245 0 0 $a Developments in T cell based cancer immunotherapies $h [electronic resource] / $c edited by Paolo A. Ascierto, David F. Stroncek, Ena Wang.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2015.
300 $a xv, 305 p. : $b ill., digital ; $c 24 cm.
490 1 $a Cancer drug discovery and development, $x 2196-9906
505 0 $a 1 New insight of peptide vaccination in cancer immunotherapy -- 2 The determinants of T cell function for effective anticancer vaccine -- 3 T cell fate in the tumor microenvironment -- 4 T cell receptor avidity and affinity and tumor specific TCR engineer -- 5 Host genetic variation and somatic alteration associated with favorable or compromised T cell function -- 6 Production of Clinical T Cell Therapies -- 7 Clinical success of adoptive cell transfer therapy using tumor infiltrating lymphocytes -- 8 Harnessing stem cell-like memory T cells for adoptive cell transfer therapy of cancer -- 9 T cell blockade- anti-CTLA4 immunotherapy against cancer and Abscopal effect in combination therapy -- 10 T cell modulation- anti-OD-1 antibodies for the treatment of cancer -- 11 T cell based therapies in combination with other procedures -- 12 Chimeric antigen receptor T cells CD19 CAR -- 13 Hematopoietic Stem Cell transplantation as immune therapy of malignancies.
520 $a This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed.
650 0 $a Cancer $x Immunotherapy. $3 406740
650 0 $a Medicine. $3 373206
650 0 $a Cancer $x Research. $3 466126
650 0 $a Immunology. $3 402223
650 0 $a Molecular biology. $3 182854
650 0 $a Cytology. $3 182853
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Molecular Medicine. $3 463625
650 2 4 $a Cell Biology. $3 463594
700 1 $a Ascierto, Paolo A. $3 635908
700 1 $a Stroncek, David F. $3 635909
700 1 $a Wang, Ena. $3 635910
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Cancer drug discovery and development. $3 463586
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-21167-1
950 $a Medicine (Springer-11650)